Brinter

Executive Summary

Brinter is a Finnish-American medical technology company pioneering the development of 3D bioprinted regenerative tissue implants, with an initial focus on orthopedic soft-tissue repair and aesthetic reconstruction. Founded in 2019 and based in Tampere, Finland, the company leverages a scalable manufacturing platform to produce biologically integrated implants that aim to shift the paradigm from synthetic replacements to true tissue regeneration. By combining proprietary bioinks, advanced printing technology, and patient-specific design, Brinter addresses significant unmet needs in orthopedics and reconstructive surgery, where current solutions often fail to restore full function or lead to complications. The company's mission is to fundamentally change human repairs by enabling the body to heal itself with living, bioprinted constructs.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human clinical trial for orthopedic soft-tissue implant50% success
• Q2 2027Strategic partnership or licensing deal with major orthopedic device company40% success
• Q3 2026Series A funding round led by prominent life sciences VC60% success